Overview
A dual GIP and GLP-1 receptor agonist that has been evaluated across a large published clinical programme in type 2 diabetes and in weight management, with well-characterised pharmacokinetics and a documented stepwise escalation schedule.
Mechanism of Action
Tirzepatide is a 39-amino-acid synthetic peptide based on the native GIP sequence, modified to activate both the GIP and GLP-1 receptors.
GLP-1 receptor activation is associated with glucose-dependent insulin release, suppression of glucagon when glucose is elevated, delayed gastric emptying and central signalling related to satiety.
GIP receptor activation is studied for complementary effects on insulin secretion and on adipose tissue nutrient handling; the research question the molecule was designed to test is whether combining the two produces effects greater than GLP-1 agonism alone.
A C20 fatty diacid chain promotes albumin binding, which is the structural basis for its extended circulating half-life.
Areas Being Studied
- Glycaemic research in type 2 diabetes
- Weight management
- Obstructive sleep apnoea research
- Cardiometabolic risk markers
Listing a research area does not imply efficacy, approval, or suitability for any use.
Research Summary
- The SURPASS programme evaluated tirzepatide across multiple comparators in type 2 diabetes and reported dose-dependent reductions in HbA1c together with body-weight change.
- The SURMOUNT programme evaluated tirzepatide in adults with obesity or overweight and reported substantial mean body-weight reductions at 72 weeks across the 5 mg, 10 mg and 15 mg maintenance doses.
- Published trials universally used a four-week escalation interval beginning at 2.5 mg, described by investigators as a tolerability measure rather than a therapeutic dose.
- Longer-term extension and cardiovascular outcome research continues to be published.
Potential Adverse Effects Reported in Research
- Nausea, diarrhoea, vomiting, constipation and dyspepsia were the most frequently reported events, predominantly mild to moderate and concentrated during escalation.
- Decreased appetite and injection-site reactions were reported.
- Reports of gallbladder-related events and, less commonly, pancreatitis appear in the trial safety literature.
- Thyroid C-cell tumour findings in rodent models are noted in regulatory documentation for the incretin class.
Reconstitution Basics
Research-grade lyophilised material is reconstituted with bacteriostatic water; the volume added determines concentration and therefore the volume drawn for a given amount.
Bacteriostatic water
Sterile water containing roughly 0.9% benzyl alcohol as a preservative, which inhibits bacterial growth in multi-access vials.
Sterile technique
Laboratory documentation describes disinfecting the stopper, using a fresh sterile needle for each access, and avoiding contact with non-sterile surfaces.
After reconstitution
Solutions are refrigerated, protected from light, and not subjected to repeated freeze–thaw cycles.
This section is educational background on laboratory handling. It is not an instruction or protocol.
Open the reconstitution calculator →Dosing & Reconstitution Guide
SURMOUNT and SURPASS protocols used a fixed once-weekly escalation over roughly 20 weeks, starting at a sub-therapeutic tolerability dose.
Protocol overview
- Once-weekly subcutaneous dosing, same weekday, with or without food.
- Four weeks minimum at each step in the label-aligned schedule.
- Rotation of injection sites (abdomen, thigh, upper arm) is described in the product literature.
- A missed dose was permitted to be taken within 4 days in trial protocols; otherwise the dose was skipped.
Dosing protocol — standard titration
| Phase | Reported dose | Notes |
|---|---|---|
| Weeks 1–4 | 2.5 mg weeklyInitiation dose; not intended as a maintenance level. | Initiation dose; not intended as a maintenance level. |
| Weeks 5–8 | 5 mg weeklyFirst maintenance-eligible dose. | First maintenance-eligible dose. |
| Weeks 9–12 | 7.5 mg weeklyEscalation step. | Escalation step. |
| Weeks 13–16 | 10 mg weeklyEscalation step. | Escalation step. |
| Week 17+ | 12.5–15 mg weeklyHighest studied maintenance range. | Highest studied maintenance range. |
Dosing protocol — gradual titration
| Phase | Reported dose | Notes |
|---|---|---|
| Weeks 1–8 | 2.5 mg weeklyExtended initiation for gastrointestinal tolerability. | Extended initiation for gastrointestinal tolerability. |
| Weeks 9–16 | 5 mg weeklyEight weeks per step instead of four. | Eight weeks per step instead of four. |
| Weeks 17–24 | 7.5 mg weeklyEscalation only if prior step is uneventful. | Escalation only if prior step is uneventful. |
| Week 25+ | 10 mg weeklyMany participants remained at mid-range doses. | Many participants remained at mid-range doses. |
Schedules summarise what appears in published studies, trial protocols or manufacturer documentation. They are reference material, not a recommendation.
Where to Buy Compounds & Supplies
External link. PepDex does not sell products and does not endorse any supplier.
Supplies needed
Lyophilised peptide vial
Sealed vial with an intact stopper and a legible mass label (mg or mcg).
Bacteriostatic water
Sterile water with ~0.9% benzyl alcohol, used where a vial will be accessed more than once. Sterile water for injection is used for single-access work.
Reconstitution syringe
A 1–3 mL syringe with a larger-gauge needle for drawing and transferring solvent.
Insulin syringe (U-100)
Fine-gauge syringe graduated in units; 100 units = 1 mL. Used for accurate small-volume measurement.
Alcohol prep pads
70% isopropyl swabs for disinfecting both vial stoppers before every access.
Sharps container
Rigid, puncture-resistant container for single-use needle disposal.
Refrigeration and light protection
2–8 °C storage plus an opaque box or the original carton for reconstituted vials.
Labels
Date of reconstitution, resulting concentration and compound name on every vial.
Reconstitution steps
- 01
Bring the vial to room temperature
Lyophilised powder is allowed to equilibrate out of the refrigerator before the stopper is pierced, which reduces condensation inside the vial.
- 02
Disinfect both stoppers
The peptide vial and the bacteriostatic water vial are each swabbed with 70% isopropyl alcohol and allowed to air dry.
- 03
Draw the calculated solvent volume
Solvent volume is chosen to produce a convenient concentration — the reconstitution calculator converts vial mass and solvent volume into concentration and syringe units.
- 04
Add the solvent slowly down the vial wall
The stream is directed against the glass rather than onto the powder cake. Peptides are shear-sensitive and direct jetting is avoided.
- 05
Dissolve without shaking
The vial is left to stand, then gently swirled or rolled. Shaking introduces foam and mechanical stress that can denature peptide chains.
- 06
Inspect the solution
Documentation describes checking for a clear, particle-free solution. Cloudiness, visible particulate or discolouration is treated as a failed preparation.
- 07
Label and refrigerate
The vial is labelled with compound, concentration and date, then stored at 2–8 °C protected from light.
Storage instructions
- Before reconstitution: lyophilised powder is kept sealed, dry and away from light; most suppliers specify refrigeration at 2–8 °C, with freezer storage for long-term holding.
- After reconstitution: refrigerated at 2–8 °C and used within the window described in the literature (commonly cited as ~28–56 days refrigerated).
- Protection from light: the vial is kept in its carton or an opaque container; repeated exposure to daylight is avoided.
- Handling: repeated freeze–thaw cycles are avoided, and vials are not left at room temperature between accesses.
- Integrity checks: any solution that becomes cloudy, discoloured or shows particulate is discarded rather than filtered.
Half-Life
~5 days
Population pharmacokinetic analyses report a terminal half-life of approximately five days, consistent with once-weekly dosing intervals used in trials.
Storage
- Before reconstitution
- Lyophilised powder stored refrigerated or frozen in a sealed vial.
- After reconstitution
- Reconstituted solution stored at 2–8 °C in published handling guidance.
- Light protection
- Protected from light; vials kept in original packaging where possible.
- Shelf-life considerations
- Handling documentation commonly describes a use-window of up to about four weeks after reconstitution under refrigeration.
Frequently Asked Questions
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
New England Journal of Medicine, 2022
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
New England Journal of Medicine, 2021
Related peptides
Retatrutide
An investigational triple agonist peptide acting at the GIP, GLP-1 and glucagon receptors. It is one of the most closely watched compounds in metabolic research because of the magnitude of body-weight change reported in published phase 2 trials.
MOTS-c
A 16-amino-acid mitochondrial-derived peptide encoded in mitochondrial DNA. Research interest centres on metabolic regulation, exercise physiology and biological ageing.
Educational reference only. Figures are compiled from published research literature. PepDex does not provide medical advice, dosing recommendations, or instructions for use.